Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9295MR)

This product GTTS-WQ9295MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ9295MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10713MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-1095
GTTS-WQ4652MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ1457MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ1118MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-927
GTTS-WQ8258MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HLX10
GTTS-WQ5062MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CaCP-29
GTTS-WQ11419MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ3878MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-100
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW